Constipation in Chemotherapy Patients: A Diagnostic Accuracy Study

Isabel Neves Duarte Lisboa¹, Jéssica Dantas de Sá Tinôco², Maria Isabel da Conceição Dias Fernandes¹*, Rammila Rayara da Silva¹, Juliana Barbosa da Silva¹, Millena Freire Delgado¹, Marcos Venícios Oliveira Lopes³, Ana Luisa Brandão de Carvalho Lira¹

Abstract

**Objective:** To analyze the accuracy of clinical indicators of constipation in cancer patients undergoing chemotherapy.

**Methods:** A diagnostic accuracy study was conducted from February to September 2018, with 240 cancer patients undergoing chemotherapy. The data collection instrument was a form with sociodemographic and clinical variables, and clinical indicators of constipation. The sensitivity and specificity of the clinical indicators of interest were calculated using a latent class analysis approach.

**Result:** The prevalence of constipation in the sample was 86.6%. The most sensitive clinical indicators were straining with defecation (100.0%), and hypoactive bowel sounds (75.0%), while headache (99.9%), abdominal pain (75.0%), pain with defecation (75.0%), straining with defecation (99.9%) and liquid stool (78.1%) were indicators with high specificity.

**Conclusion:** A set of six clinical indicators was significantly associated with the occurrence of constipation in cancer patients undergoing chemotherapy, especially straining with defecation. These indicators can be used by nurses to identify constipation and propose prompt and effective interventions.

**Keywords:** Drug therapy- constipation- data accuracy- nursing

Asian Pac J Cancer Prev; 22 (9), 3017-3021

Introduction

Cancer is the second-leading cause of death worldwide and affected approximately 9.6 million people in 2018 (Pan American Health Organization, 2019). Chemotherapy is the main treatment and corresponds to the administration of oral or intravenous cytotoxic agents, but its side effects are systemic (Brenner et al., 2017; Roy and Saikia, 2016). Chemotherapy may cause damage to enteric neurons and gastrointestinal dysfunction. Such damage persists for years after treatment, affecting patients’ quality of life (Brenner et al., 2017; Escalante et al., 2017).

One of the common side effects of chemotherapy is constipation, a decrease in the normal frequency of defecation accompanied by difficult or incomplete passage of stool, or passage of excessively hard, dry stool (Herdman and Kamitsuru, 2018). Constipation is a common problem in cancer patients, with a prevalence of 40% to 90% (Larkin et al., 2018; Staats et al., 2004). The occurrence of this problem ranges from mild to severe and may cause depression, anxiety, nausea, vomiting, hemorrhoids, anal fissure, intestinal obstruction, and urinary retention (Larkin et al., 2018; Dhingra et al., 2013; Thorpe, 2001).

Patients with untreated constipation incur expenses for the health system. Thus, accurate identification of constipation can contribute to early treatment and lower health costs (Larkin et al., 2018; Iskedjian et al., 2011; Wee et al., 2010).

Although the manifestations of constipation are commonly found in clinical practice (Agra et al., 2013; Brazil, 2009), the process by which nurses infer this problem is not always based on accurate clinical indicators, thus, it is of fundamental importance that nurses use accurate indicators in clinical practice to support the inference of constipation in cancer patients. The development of diagnostic accuracy studies on the sensitivity and specificity of specific clinical indicators is indispensable for the strengthening of nursing practice (Silva et al., 2017).

Given the above, this study hypothesizes that there is a set of clinical indicators that best represent constipation in cancer patients undergoing chemotherapy. This study aimed to analyze the accuracy of clinical indicators of constipation in cancer patients undergoing chemotherapy.

¹Department of Nursing, Federal University of Rio Grande do Norte, Natal, Brazil. ²Department, State University of Rio Grande do Norte, Caicó, Brazil. ³Department of Nursing, Federal University of Ceará, Fortaleza, Brazil. *For Correspondence: bebel_6@hotmail.com

Asian Pacific Journal of Cancer Prevention, Vol 22 3017
Materials and Methods

Study design and setting
A diagnostic accuracy study was carried out in a reference cancer service in Brazil. A prospective approach was used and the data collection was planned before the index test and reference standards were performed (Boissu et al., 2015).

Population
The population consisted of patients undergoing chemotherapy at the service mentioned above. The sample size was estimated using the method described by Swanson et al., (2012) based on the Item Response Theory, recommended for diagnostic accuracy studies based on latent class analysis. In this method, the author proposes a predefined number of individuals per clinical indicator investigated. The sample calculation used a constant of nine for each of the 26 investigated clinical indicators. Thus, the sample was 240 patients.

A convenience, consecutive sampling method was used in this study. Patients with a medical diagnosis of cancer were identified by an oncologist specialist researcher using the database of the oncology hospital. Afterward, the following inclusion criteria were applied: age over 18 years, antineoplastic chemotherapy or chemotherapy combined with radiotherapy, and hormone therapy. The exclusion criteria were patients disoriented in time, place, and/or person, and patients undergoing chemotherapy for the first time (due to the absence of effects).

Data collection
The data collection occurred from February to September 2018. The data collection instrument consisted of a form with sociodemographic variables (age, gender, marital status, education, personal and family income, and religion), clinical variables (treatment time, type of cancer, and medications used), and clinical indicators of constipation covered by the NANDA-I taxonomy of nursing diagnoses (Herdman and Kamitsuru, 2018) (abdominal pain, abdominal tenderness with palpable muscle resistance, abdominal tenderness without palpable muscle resistance, anorexia, atypical presentations in older adults, borborygmi, bright red blood with stool, change in bowel pattern, decrease in stool frequency, decrease in stool volume, distended abdomen, fatigue, hard formed stool, headache, hyperactive bowel sounds, hypoactive bowel sounds, indigestion, liquid stool, pain with defecation, palpable abdominal mass, percutsed abdominal dullness, rectal fullness, rectal pressure, severe flatus, straining with defecation, and vomiting).

The main investigator used a standard operating protocol with operational definitions constructed for the identification of the clinical indicators of interest based on concepts from the Word Gastroenterology Organization (2010).

Subsequently, the investigator assessed each clinical indicator and classified it as present or absent, except for hard formed stool, liquid stool, change in bowel pattern, decreased stool frequency, and anorexia, which were considered present or absent through measurement using validated tools.

The indicators hard formed stool and liquid stool were measured using the Bristol Scale (Lewis and Heaton, 1997), which allows the visual classification of stools into seven different types. The indicators change in bowel pattern and decrease in stool frequency were measured based on the criteria established in the Rome Consensus (Drossman, 2016). Anorexia was measured using the body mass index (Stengel et al., 2013).

Data analysis
Data were analyzed using the R software version 3.0.2. The descriptive analyses included frequencies, central tendency, and dispersion measures. The Kolmogorov-Smirnov test was used to determine normality.

Measures of specificity and sensitivity were obtained for each clinical indicator of constipation based on mathematical modeling, the latent class. This model indicates that unobservable or latent data determines the relationship between observable data (Collins and Lanza, 2010). In this study, the unobservable or latent data was constipation, and observable data corresponded to the clinical indicators investigated. Sensitivity is defined as the presence of a given clinical indicator when the outcome (constipation) is present; while specificity indicates the absence of a given indicator in the absence of the outcome (Lopes et al., 2012).

This study used two latent class models with random effects to obtain sensitivity and specificity measures, and 95% confidence intervals. An initial null model contemplated all clinical indicators studied. Then, the likelihood ratio test (G2) was applied to verify the effectiveness of the latent class model adjustment. Clinical indicators were considered statistically significant if at least one of the confidence intervals (either for sensitivity or specificity) were above 0.5 (Collins and Lanza, 2010). Indicators that exhibited the worst performance for the area under the ROC curve were sequentially removed until the latent class model attained the proper fit. The area under ROC curves for dichotomous data is calculated based on the average sensitivity and specificity, namely (Se+Sp)/2. The adjusted model comprised the set of clinical indicators that presented the better best performance in terms of sensitivity and specificity to extract the latent variable structure.

Ethical considerations
The study was approved by the ethics committee of the university in which the study was undertaken, and all participants signed informed consents before participation.

Results

Population general data
Of the 240 cancer patients undergoing chemotherapy, 83.8% were female, 83.8% were retirees, 81.3% had a religion, and 53.8% were married. The average age and length of education were 55.6 years (SD = 12.0) and 7.5 years (SD = 5.2).

The patients presented an average length of cancer...
diagnosis of 23.4 months (SD = 39.7), and the main form of cancer was breast cancer (43.8%). The most prevalent medications used were gastric and corticosteroid drugs (100%), antiemetic drugs (95.8%), and antiallergic drugs (40.8%).

Clinical indicators of constipation
The frequency of the clinical indicators of constipation is presented in Table 1. The most frequent clinical indicators were straining with defecation, decreased stool frequency, change in bowel pattern, hard formed stool, hypoactive bowel sounds, pain with defecation, and decreased stool volume. The following six clinical indicators were not included in the table mentioned above as they were absent: atypical presentations in older adults, borborygmi, distended abdomen, palpable abdominal mass, abdominal tenderness with palpable muscle resistance, and abdominal tenderness without palpable muscle resistance.

| Clinical indicators | n  | %   |
|---------------------|----|-----|
| Straining with defecation | 208 | 86.7 |
| Decrease in stool frequency | 208 | 86.7 |
| Change in bowel pattern | 192 | 80.0 |
| Hard, formed stool | 190 | 79.2 |
| Hypoactive bowel sounds | 171 | 71.3 |
| Pain with defecation | 139 | 57.9 |
| Decrease in stool volume | 135 | 56.3 |
| Fatigue | 117 | 48.8 |
| Anorexia | 116 | 48.3 |
| Severe flatus | 90 | 37.5 |
| Hyperactive bowel sounds | 69 | 28.8 |
| Percussed abdominal dullness | 56 | 23.3 |
| Indigestion | 55 | 22.9 |
| Bright red blood with stool | 44 | 18.3 |
| Rectal fullness | 35 | 14.6 |
| Rectal pressure | 35 | 14.6 |
| Headache | 34 | 14.2 |
| Liquid stool | 33 | 13.8 |
| Vomiting | 13 | 5.4 |
| Abdominal pain | 9 | 3.8 |

From the set of clinical indicators analyses together, it was possible to highlight the occurrence of the latent variable, constipation. The adjusted model presented a prevalence of constipation of 86.6% in the sample studied.

### Discussion

The present study found a high prevalence of constipation among females and breast cancer patients. These data corroborate the current scenario since breast cancer is the most common type of cancer in women (Brazil, 2018).

The most used medications in the sample studied were gastric medications, corticosteroids, and antiemetic drugs. The drugs used in chemotherapy act on fast-growing cells, such as gastrointestinal, capillary, and immune cells. As a result, adverse effects can occur, such as nausea, vomiting, diarrhea, alopecia, and increased susceptibility to infections. Thus, the use of different pharmacological classes to treat undesirable symptoms like the ones mentioned above, is common (Silva and Comarella, 2013).

Constipation was present in 86.6% of cancer patients in this study. The literature corroborates that constipation is the most frequent adverse effect in the population studied, especially in those receiving opioid analgesics or drugs with anticholinergic properties (Wickham, 2017).

Constipation contributes to decreased quality of life in cancer patients. When left untreated, it results in great

### Table 1. Frequency of Clinical Indicators of the Nursing Diagnosis of Constipation in Cancer Patients Undergoing Chemotherapy

| Clinical indicators | n   | %   |
|---------------------|-----|-----|
| Straining with defecation | 208 | 86.7 |
| Decrease in stool frequency | 208 | 86.7 |
| Change in bowel pattern | 192 | 80.0 |
| Hard, formed stool | 190 | 79.2 |
| Hypoactive bowel sounds | 171 | 71.3 |
| Pain with defecation | 139 | 57.9 |
| Decrease in stool volume | 135 | 56.3 |
| Fatigue | 117 | 48.8 |
| Anorexia | 116 | 48.3 |
| Severe flatus | 90 | 37.5 |
| Hyperactive bowel sounds | 69 | 28.8 |
| Percussed abdominal dullness | 56 | 23.3 |
| Indigestion | 55 | 22.9 |
| Bright red blood with stool | 44 | 18.3 |
| Rectal fullness | 35 | 14.6 |
| Rectal pressure | 35 | 14.6 |
| Headache | 34 | 14.2 |
| Liquid stool | 33 | 13.8 |
| Vomiting | 13 | 5.4 |
| Abdominal pain | 9 | 3.8 |

### Table 2. Accuracy Measures of the Clinical Indicators of Constipation from the Adjusted Latent Class Model

| Clinical Indicators | Se (%) | 95% CI      | Sp (%) | 95% CI      |
|---------------------|--------|-------------|--------|-------------|
| Headache            | 16.3   | 0.1192 - 0.2150 | 99.9 | 0.9998 - 10,000 |
| Abdominal pain      | 0.4    | 0.0002 - 0.0.9768 | 75.0 | 0.5434 - 0.8764 |
| Pain with defecation| 62.9   | 0.5553 - 0.6930 | 75.0 | 0.1159 - 0.9709 |
| Straining with defecation | 100.0 | 0.9998 - 10,000 | 99.9 | 0.9448 - 10,000 |
| Liquid stool        | 12.5   | 0.0910 - 0.1827 | 78.1 | 0.5750 - 0.8917 |
| Hypoactive bowel sounds | 75.0  | 0.6877 - 0.7992 | 53.1 | 0.3157 - 0.7184 |

Prevalence: 86.66%

| G^2 | df | p  |
|-----|----|----|
| 60.98 | 50 | 0.137 |

Abbreviations: Se, sensitivity; Sp, specificity; CI, Confidence interval.
discomfort and negative consequences, some of which, life-threatening, such as bowel impaction and perforation (Woolery et al., 2008). Thus, nurses should use accurate clinical indicators to confirm the diagnosis of constipation and intervene in this problem promptly and based on evidence.

This study presents a set of six clinical indicators (straining with defecation, hypoactive bowel sounds, headache, abdominal pain, pain with defecation, and liquid stool) significantly associated with the occurrence of constipation in cancer patients undergoing chemotherapy. The literature confirms the relationship between constipation and the clinical indicators mentioned above (Emmanuel et al., 2017; Stubhaug, 2016). Therefore, the nurse should assess the patient’s history and perform a physical examination based mainly on accurate constipation indicators.

The clinical indicator straining with defecation can predict constipation accurately. The literature shows that straining with defecation, hardened stools, abdominal distension, and incomplete bowel movement are clinical manifestations of drug-induced constipation (Stubhaug, 2016).

The clinical indicator hypoactive bowel sounds was considered sensitive for the detection of constipation. This clinical indicator often manifests itself together with hard and dry stools, which pass slowly through the intestines causing abdominal distension and a reduced frequency of bowel movements. As a result, uncomfortable and debilitating reactions that characterize constipation are experienced by the patient (Locasale et al., 2016).

Headache, which had a high specificity value, can be associated with gastrointestinal disorders (Martari et al., 2018). The brain and gut have a strong two-way connection via neural and immune pathways. This gut-brain axis plays an important role in the association between gastrointestinal disorders and headache (Mayer et al., 2011). Abdominal pain and pain with defecation were evidenced as specific clinical indicators. The literature notes pain as one of the main characteristics in these patients (Rhondali et al., 2013). Thus, it is relevant to accurately recognize constipation to relieve patients’ discomfort, providing adequate and comfortable bowel habits (Larkin et al., 2008; Wickham, 2017).

The clinical indicator liquid stools was specific for the detection of constipation. Episodes of liquid stools may occur as a consequence of prolonged constipation and paradoxical diarrhea. The mechanism occurs through the irritation of the rectal mucosa by the presence of fecaloma, leading to the production of a large amount of mucus, which resembles diarrheal stools (Wald, 2016). Nurses must correctly identify constipation in cancer patients and promote prompt and cost-effective interventions to the patient’s well-being. Dietary and lifestyle modification can be recommended by nurses (Toner and Claro, 2012) identifying accurate identification clinical indicators of constipation.

This study provides estimates of the accuracy of clinical indicators of constipation in patients undergoing chemotherapy that nurses can use to propose prompt and effective interventions. Therefore, this knowledge contributes to nursing science and enhances the clinical nursing practice in the cancer care field.

The limitations of this study were data collection conducted in only one center in Brazil and the adjustment in the latest model carried out to identify accurate indicators. Thus, multicenter accuracy studies on constipation are recommended to compare the present findings.

A high prevalence of constipation was found among cancer patients undergoing chemotherapy. The sensitive clinical indicators were straining with defecation and hypoactive bowel sounds. The indicators headache, abdominal pain, pain with defecation, straining with defecation, and liquid stool were specific. The indicator straining with defecation was considered a reliable predictor of constipation. In conclusion, nurse practitioners should identify sensitive and specific clinical indicators to confirm chronic constipation in cancer patients undergoing chemotherapy.

Acknowledgments

This research is part of the master’s thesis entitled “Accuracy of clinical indicators of the nursing diagnosis of constipation in cancer patients undergoing antineoplastic chemotherapy” presented at the Graduate Program in Nursing at the Federal University of Rio Grande of Norte.

Research Ethics Committee

This research was approved by the ethics committee of the “Liga Norterriograndense contra o câncer” under opinion nº 2.417.240.

Conflicts of interest

All authors have no conflicts of interest to report.

References

Agra G, Fernandes MA, Platel ICS (2013). Constipation in patients with advanced cancer in use of the opioid. The World of Health, 37, 472-78.
Bossuyt PM, Reitsma JB, Bruns DE, et al (2015). STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ, 351, 1-9.
Brazil (2018). Estimates 2018: incidence of cancer in Brazil. Rio de Janeiro (RJ): INCA.
Brenner DM, Stern E, Cash BD (2017). Opioid-related constipation in patients with non-cancer pain syndromes: a review of evidence-based therapies and justification for a change in nomenclature. Curr Gastroenterol Rep, 19, 1-6.
Collins LM, Lanza ST (2010). Latent class and latent transition analysis: With applications in the social behavioral, and health sciences. Wiley, Hoboken.
Dhingra L, Shuk E, Grossman B, et al (2013). A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med, 27, 447-56.
Drossman DA (2016). Functional gastrointestinal disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology, 150, 1262-79.
Emmanuel A, Johnson M, McSkimming P, Dickerson S (2017).
Laxatives do not improve symptoms of opioid-induced constipation: results of a patient survey. *Pain Med*, 18, 1932-40.

Escalante J, McQuade RM, Stojanova V, Nurgali K (2017). Impact of chemotherapy on gastrointestinal functions and the enteric nervous system. *Maturitas*, 105, 23-9.

Herdmann TH, Kamitsuru S (2018). Nursing Diagnoses: Definitions & Classification 2018-2020. Constipação. Artmed, Porto Alegre. pp 352-54.

Iskedjian M, Iyer S, Librach L, et al (2011). Methyl salicylate in the treatment of opioid-induced constipation in cancer patients receiving palliative care: willingness-to-pay and cost-benefit analysis. *J Pain Symptom Manage*, 41, 104-15.

Larkin P, Cherny NL, La Carpia D, et al (2018). Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. *Ann Oncol*, 29, 111-25.

Larkin PJ, Sykes NP, Centeno C, et al (2008). The management of constipation in palliative care: clinical practice recommendations. *Palliat Med*, 22, 796-807.

Lewis SJ, Heaton KW (1997). Stool form scale as a useful guide to intestinal transit time. *Scand. J Gastroenterol*, 32, 920-4.

Locasale RJ, Datto C, Wilson H, Yeomans K, Coyne KS (2016). The burden of opioid-induced constipation: Discordance Between Patient and Health Care Provider Reports. *J Manag Care Spec Pharm*, 22, 236-45.

Lopes MVO, Silva VM, Araújo TL (2012). Methods for establishing the accuracy of clinical indicators in predicting nursing diagnoses. *Int J Nurs Stud*, 23, 134-9.

Martani F, Ghorbani Z, Abolhasani M, et al (2018). Comorbidity of gastrointestinal disorders, migraine, and tension-type headache: a cross-sectional study in Iran. *Neurol Sci*, 39, 63-70.

Mayer EA, Tillisch K (2011). The brain-gut axis in abdominal pain syndromes. *Annu Rev Med*, 62, 381-96.

Pan American Health Organization (2019). Cancer: Pan American Health Organization. Available at: https://www.paho.org/en/topics/cancer (Accessed: 5 July 2021).

Rhondali W, Nguyen L, Palmer L (2013). Self-reported constipation in patients with advanced cancer: a preliminary report. *J Pain Symptom Manage*, 45, 23-32.

Roy PS, Saikia BJ (2016). Cancer and cure: A critical analysis. *Indian J Cancer*, 53, 441-42.

Silva FCM, Comarella L (2013). Adverse effects associated with antineoplastic chemotherapy: a survey of patients from a hospital in the state of Paraná. *Rev. Uniandrade*, 14, 263-77.

Silva RA, Melo GAA, Caetano JA, et al (2017). Accuracy of nursing diagnosis “readiness for enhanced hope” in patients with chronic kidney disease. *Rev Gaiach Enferm*, 38, 1-8.

Staats PS, Markowitz J, Schein J (2004). Incidence of constipation associated with long-acting opioid therapy: a comparative study. *South Med J*, 97, 129-34.

Stengel A, Hofmann T, Goebel-Stengel M, et al (2013). Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity – Correlation with body mass index. *Peptides*, 39, 125-30.

Stubhaug A (2016). Advances in understanding and treatment of opioid-induced-bowel-dysfunction, opioid-induced-constipation in particular Nordic recommendations based on multi-specialist input. *Scand. J Pain*, 11, 163-64.

Swanson SA, Lindenberg K, Bauer S, Crosby RD (2012). A Monte Carlo investigation of factors influencing latent class analysis: An application to eating disorder research. *Int J Eat Disord*, 45, 677-84.

Thorpe DM (2001). Management of opioid-induced constipation. *Curr Pain Headache Rep*, 5, 237-40.

Toner F, Claro E (2012). Preventing, assessing, and managing constipation in older adults. *Nurs*, 42, 32-9.

Wald A (2016). Constipation: Advances in Diagnosis and Treatment. *JAMA*, 315, 185-91.

Woo, B, Adams A, Thompson K, et al (2010). How much does it cost a specialist palliative care unit to manage constipation in patients receiving opioid therapy?. *J Pain Symptom Manage*, 39, 644-54.

Wickham RJ (2017). Managing constipation in adults with cancer. *J Adv Pract Oncol*, 8, 149-61.

Woolery M, Bisanz A, Lyons HF, et al (2008). Putting evidence into practice: evidence-based interventions for the prevention and management of constipation in patients with cancer. *Clin J Oncol Nurs*, 12, 317-37.

WGO (2010). WGO Practice Guidelines. Constipação: uma perspectiva mundial. WGO: Milwaukee, pp 11-12.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.